COMP <GO>
USPH vs OMDA // PIOTROSKI F-SCORE QUALITY
U.S. Physical Therapy Inc. (NYSE) VS. Omada Health Inc. (NASDAQ) • 15-METRIC TALLY: USPH 8
— OMDA 3
▲ PIOTROSKI F-SCORE QUALITY LEADER: USPH
LAST: $86.57 (+1.47%) • MKT CAP: $1.29B
piotroski-score
8/9
LAST: $19.65 (+2.45%) • MKT CAP: $1.20B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (USPH VS. OMDA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | USPH | OMDA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 19.20% | 65.70% | -46.50 | OMDA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.50% | -15.70% | +27.20 | USPH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.81% | 1.41% | +4.40 | USPH | /fcf-yield <GO> |
| Operating Margin | 11.10% | -4.60% | +15.70 | USPH | /operating-margins <GO> |
| Net Profit Margin | 5.10% | -4.90% | +10.00 | USPH | /net-margins <GO> |
| Revenue Growth (YoY) | 16.30% | 53.20% | -36.90 | OMDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.12% | 0.00% | +2.12 | USPH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.94 | 8.93 | -5.99 | OMDA | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 7/9 | +1.00 | USPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.3 | 43.6 | +8.69 | USPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.4x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.29B | $1.20B | $88.9M | USPH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | USPH REV | OMDA REV | USPH GROSS % | OMDA GROSS % | USPH FCF | OMDA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $781.0M | $260.2M | 19.2% | 65.7% | $75.1M | $16.9M |
| FY 2024 | $671.3M | $169.8M | 18.5% | 60.6% | $74.9M | -$34.8M |
| FY 2023 | $604.8M | $122.8M | — | — | $82.0M | -$49.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
USPH // BETA —
OMDA // BETA —